• Explore /
  • Poster
  • / Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

Updated overall survival (OS) and progression-free survival (PFS) by blinded independent central review (BICR) of sunitinib (SU) versus placebo (PBO) for patients (Pts) with advanced unresectable pancreatic neuroendocrine tumors (NET).

Abstract Poster

Authors

null

E. Raymond

Beaujon University Hospital, Clichy, France

E. Raymond , P. Niccoli , J. Raoul , Y. Bang , I. Borbath , C. Lombard-Bohas , J. W. Valle , P. Metrakos , D. Smith , A. Vinik , J. Chen , D. Hoersch , D. E. Castellano , H. F. Kennecke , J. Picus , G. Van Hazel , D. Lu , R. C. Chao , S. Patyna , E. Van Cutsem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2011 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Other GI Cancer

Clinical Trial Registration Number

NCT00428597, NCT00443534, NCT00428220

Citation

J Clin Oncol 29: 2011 (suppl; abstr 4008)

Abstract #

4008

Poster Bd #

1

Abstract Disclosures

Similar Posters

First Author: Aaron Vinik

First Author: Eric Van Cutsem

First Author: Paul D. Nathan

First Author: Viktor Grünwald